Literature DB >> 20663900

Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.

Rong Chen1, Sherri Chubb, Tiewei Cheng, Rachael E Hawtin, Varsha Gandhi, William Plunkett.   

Abstract

SNS-032 is a potent inhibitor of cyclin-dependent kinases (Cdk) 2, 7, and 9 that regulate the cell cycle and transcription. Our studies in indolent primary chronic lymphocytic leukemia cells showed that SNS-032 inhibited transcription, diminished the antiapoptotic protein Mcl-1, and induced apoptosis. The present study focuses on evaluating this compound in four proliferating mantle cell lymphoma lines (Jeko-1, Granta 519, Mino, and SP-53). Consistent with its action against Cdk9 and Cdk7, SNS-032 inhibited the phosphorylation of RNA pol II in all four lines and blocked RNA synthesis. The transcripts and protein levels of short-lived proteins decreased, including cyclin D1 and Mcl-1. Cell growth was inhibited in a concentration-dependent manner in all lines. Apoptosis was induced in JeKo-1, Mino, and SP-53 cells without disrupting cell cycle distribution. However, apoptosis was limited in Granta cells; rather, there was a significant reduction of clonogenic survival. Small interfering RNA was used to specifically knock down Mcl-1 and cyclin D1 in JeKo-1 and Granta cells. Knocking down Mcl-1 induced significant apoptosis in Jeko-1 cells but not Granta cells. Reducing cyclin D1, rather than Mcl-1, was associated with loss of clonogenic survival in Granta cells. Thus, these results indicated that mantle cell lymphoma cell lines have distinct mechanisms sustaining their survival, and the mechanism of action of SNS-032 is dependent on the biological context of an individual line. (c)2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20663900      PMCID: PMC2929954          DOI: 10.1158/0008-5472.CAN-09-3578

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  Characterization of 4 mantle cell lymphoma cell lines.

Authors:  Hesham M Amin; Timothy J McDonnell; L Jeffrey Medeiros; Georgios Z Rassidakis; Vasiliki Leventaki; Sean L O'Connor; Michael J Keating; Raymond Lai
Journal:  Arch Pathol Lab Med       Date:  2003-04       Impact factor: 5.534

2.  Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression.

Authors:  Joseph D Khoury; L Jeffrey Medeiros; George Z Rassidakis; Timothy J McDonnell; Lynne V Abruzzo; Raymond Lai
Journal:  J Pathol       Date:  2003-01       Impact factor: 7.996

Review 3.  The caspase-RB connection in cell death.

Authors:  X Tan; J Y Wang
Journal:  Trends Cell Biol       Date:  1998-03       Impact factor: 20.808

4.  Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.

Authors:  B Carlson; T Lahusen; S Singh; A Loaiza-Perez; P J Worland; R Pestell; C Albanese; E A Sausville; A M Senderowicz
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

5.  The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.

Authors:  Mi-Ae Lyu; Lawrence H Cheung; Walter N Hittelman; John W Marks; Ricardo C T Aguiar; Michael G Rosenblum
Journal:  Mol Cancer Ther       Date:  2007-01-31       Impact factor: 6.261

6.  A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.

Authors:  Rong Chen; Varsha Gandhi; William Plunkett
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

7.  U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome.

Authors:  Güliz Gürel; Gregor Blaha; Peter B Moore; Thomas A Steitz
Journal:  J Mol Biol       Date:  2009-04-09       Impact factor: 5.469

8.  Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene.

Authors:  S E Bodrug; B J Warner; M L Bath; G J Lindeman; A W Harris; J M Adams
Journal:  EMBO J       Date:  1994-05-01       Impact factor: 11.598

9.  Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice.

Authors:  H Lovec; A Grzeschiczek; M B Kowalski; T Möröy
Journal:  EMBO J       Date:  1994-08-01       Impact factor: 11.598

10.  Cell Line Data Base: structure and recent improvements towards molecular authentication of human cell lines.

Authors:  Paolo Romano; Assunta Manniello; Ottavia Aresu; Massimiliano Armento; Michela Cesaro; Barbara Parodi
Journal:  Nucleic Acids Res       Date:  2008-10-15       Impact factor: 16.971

View more
  15 in total

1.  The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells.

Authors:  Wei Fu; Le Ma; Baoky Chu; Xue Wang; Marilyn M Bui; Jennifer Gemmer; Soner Altiok; W Jackson Pledger
Journal:  Mol Cancer Ther       Date:  2011-04-13       Impact factor: 6.261

2.  Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs.

Authors:  Nadine Löschmann; Martin Michaelis; Florian Rothweiler; Richard Zehner; Jaroslav Cinatl; Yvonne Voges; Mohsen Sharifi; Kristoffer Riecken; Jochen Meyer; Andreas von Deimling; Iduna Fichtner; Taravat Ghafourian; Frank Westermann; Jindrich Cinatl
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

Review 3.  Cyclin-dependent kinase inhibitor therapy for hematologic malignancies.

Authors:  Prithviraj Bose; Gary L Simmons; Steven Grant
Journal:  Expert Opin Investig Drugs       Date:  2013-05-06       Impact factor: 6.206

4.  Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms.

Authors:  Robert Albero; Anna Enjuanes; Santiago Demajo; Giancarlo Castellano; Magda Pinyol; Noelia García; Cristina Capdevila; Guillem Clot; Helena Suárez-Cisneros; Mariko Shimada; Kennosuke Karube; Mónica López-Guerra; Dolors Colomer; Sílvia Beà; José Ignacio Martin-Subero; Elías Campo; Pedro Jares
Journal:  J Clin Invest       Date:  2018-08-20       Impact factor: 14.808

5.  SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.

Authors:  Haitao Meng; Yingming Jin; Hui Liu; Liangshun You; Chunmei Yang; Xue Yang; Wenbin Qian
Journal:  J Hematol Oncol       Date:  2013-02-18       Impact factor: 17.388

6.  WIN55,212-2 induces cytoplasmic vacuolation in apoptosis-resistant MCL cells.

Authors:  A M Wasik; S Almestrand; X Wang; K Hultenby; Å-L Dackland; P Andersson; E Kimby; B Christensson; B Sander
Journal:  Cell Death Dis       Date:  2011-11-03       Impact factor: 8.469

7.  Analysis of apoptosis methods recently used in Cancer Research and Cell Death & Disease publications.

Authors:  O Bucur; A L Stancu; R Khosravi-Far; A Almasan
Journal:  Cell Death Dis       Date:  2012-02-02       Impact factor: 8.469

8.  RNA inhibition highlights cyclin D1 as a potential therapeutic target for mantle cell lymphoma.

Authors:  Shiri Weinstein; Rafi Emmanuel; Ashley M Jacobi; Avigdor Abraham; Mark A Behlke; Andrew G Sprague; Tatiana I Novobrantseva; Arnon Nagler; Dan Peer
Journal:  PLoS One       Date:  2012-08-14       Impact factor: 3.240

9.  P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.

Authors:  Nitesh P Shirsath; Sonal M Manohar; Kalpana S Joshi
Journal:  Mol Cancer       Date:  2012-10-18       Impact factor: 27.401

10.  Transcription inhibition as a therapeutic target for cancer.

Authors:  Christine M Stellrecht; Lisa S Chen
Journal:  Cancers (Basel)       Date:  2011-11-23       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.